Production (Stage)
Neuphoria Therapeutics Inc.
NEUP
$6.87
-$0.28-3.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -- | -15.42M | -18.10M |
| Total Depreciation and Amortization | -- | -- | -- | 828.80K | 828.90K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -- | 432.50K | -207.60K |
| Change in Net Operating Assets | -- | -- | -- | -74.60K | 1.49M |
| Cash from Operations | -- | -- | -- | -14.24M | -15.99M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -71.30K | -63.60K |
| Cash from Investing | -- | -- | -- | -141.00K | -63.60K |
| Total Debt Issued | -- | -- | -- | -380.90K | -- |
| Total Debt Repaid | -- | -- | -- | 28.30K | 26.30K |
| Issuance of Common Stock | -- | -- | -- | 10.29M | 8.89M |
| Repurchase of Common Stock | -- | -- | -- | -- | -539.70K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 1.91M | -438.90K |
| Cash from Financing | -- | -- | -- | 11.85M | 7.93M |
| Foreign Exchange rate Adjustments | -- | -- | -- | 165.80K | -116.40K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -- | -2.30M | -8.24M |